Rosiglitazone ameliorates endotoxin-induced organ damage in conscious rats

Biological Research for Nursing

Volumn 13, Issue 1, 2011, Pages 38-43

  Wu, Wen Tien ^a,c   Lee, Chia Chi ^b   Lee, Chung Jen ^b   Subeq, Yi Maun ^a   Lee, Ru Ping ^a   Hsu, Bang Gee ^a,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

conscious rat; endotoxin shock; rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; CONSCIOUSNESS; DRUG EFFECT; HEART RATE; IMMUNOLOGY; MALE; METABOLISM; RAT; SEPTIC SHOCK; UREA NITROGEN BLOOD LEVEL; WISTAR KYOTO RAT;

ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPARTATE AMINOTRANSFERASES; BLOOD PRESSURE; BLOOD UREA NITROGEN; CONSCIOUSNESS; CREATINE KINASE; HEART RATE; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDES; MALE; RATS; RATS, INBRED WKY; SHOCK, SEPTIC; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650781526     PISSN: 10998004     EISSN: 15524175     Source Type: Journal    
DOI: 10.1177/1099800409353358     Document Type: Article

References (25)

1. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M.R. (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine, 29, 1303-1310.
2. Ayala, A., Lomas, J.L., Grutkoski, P.S., & Chung, C.S. (2003). Pathological aspects of apoptosis in severe sepsis and shock? The International Journal of Biochemistry & Cell Biology, 35, 7-15.
3. 3, reduces the development of non-septic shock induced by zymosan in mice. Critical Care Medicine, 32, 457-466.
4. Hannele, Y.J. (2004). Drug therapy: Thiazolidinediones. The New England Journal of Medicine, 351, 1106-1108.
5. Haveman, J.W., Muller Kobold, A.C., Tervaert, J.W., van den Berg, A.P., Tulleken, J.E., Kallenberg, C.G.,et al.(1999). The central role of monocytes in the pathogenesis of sepsis: Consequences for immunomonitoring and treatment. The Netherlands Journal of Medicine, 55, 132-141.
6. Hsu, B.G., Lee, R.P., Yang, F.L., Harn, H.J., & Chen, H.I. (2006). Post-treatment with N-acetylcysteine ameliorates the endotoxin shock-induced organ damage in conscious rats. Life Sciences, 79, 2010-2016.
7. Hsu, B.G., Yang, F.L., Lee, R.P., Peng, T.C., & Chen, H.I. (2005). Posttreatment with low dose propofol on inflammation responses to lipopolysaccharide-induced shock in conscious rats. Clinical and Experimental Pharmacology and Physiology, 32, 24-29.
8. Jiang, C., Ting, A.T., & Seed, B. (1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 391, 82-86.
9. Kuboki, S., Shin, T., Huber, N., Eismann, T., Galloway, E., Schuster, R.,et al.(2008). Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. Hepatology, 47, 215-224.
10. Lee, S., Kim, W., Kang, K.P., Moon, S.O., Sung, M.J., Kim, D.H.,et al.(2005). Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrology, Dialysis, Transplantation, 20, 1057-1065.
11. 3). The Journal of Biological Chemistry, 270, 12953-12956.
12. Liu, D., Zeng, B.X., Zhang, S.H., Wang, Y.L., Zeng, L., Geng, Z.L.,et al.(2005). Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats. Critical Care Medicine, 33, 2309-2316.
13. Marik, P.E., & Raghavan, M. (2004). Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Medicine, 30, 748-756.
14. Mayeux, P.R. (1997). Pathobiology of lipopolysaccharide. Journal of Toxicology and Environmental Health, 51, 415-435.
15. McCowen, K.C., Malhotra, A., & Bistrian, B.R. (2001). Stress-induced hyperglycemia. Critical Care Clinics, 17, 107-124.
16. Oberholzer, A., Oberholzer, C., & Moldawer, L.L. (2001). Sepsis syndromes: Understanding the role of innate and acquired immunity. Shock, 16, 83-96.
17. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., & Glass, C.K. (1998). The peroxisome proliferator activated receptor gamma is a negative regulator of macrophage activation. Nature, 391, 79-82.
18. Riedemann, N.C., Guo, R.F., & Ward, P.A. (2003). Novel strategies for the treatment of sepsis. Nature Medicine, 9, 517-524.
19. Senftleben, U., & Karin, M. (2002). The IKK/NF-kappaB pathway. Critical Care Medicine, 30, S18-S26.
20. Siddiqui, A.M., Cui, X., Wu, R., Dong, W., Zhou, M., Hu, M.,et al.(2006). The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-. Critical Care Medicine, 34, 1874-1882.
21. Vanhorebeek, I., Langouche, L., & Van den Berghe, G. (2007). Tight blood glucose control: What is the evidence? Critical Care Medicine, 35, S496-S502.
22. Wagstaff, A.J., & Goa, K.L. (2002). Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs, 62, 1805-1837.
23. Yue, Tl. TL., Chen, J., Bao, W., Narayanan, P.K., Bril, A., Jiang, W.,et al.(2001). In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation, 104, 2588-2594.
24. Zhou, M., Wu, R., Dong, W., Jacob, A., & Wang, P. (2008). Endotoxin downregulates peroxisome proliferator-activated receptor-gamma via the increase in TNF-alpha release. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 294, R84-R92.
25. Zingarelli, B., & Cook, J.A. (2005). Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock, 23, 393-399.